

(19) World Intellectual Property Organization
International Bureau



G00002

(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060392 A3

(51) International Patent Classification⁷: **A61K 31/505**,
31/495, 31/50, 31/535, 31/40, 31/47, 31/44, 31/425, 31/42,
31/415, A61P 25/00, C07D 209/02, 209/82, 215/38,
231/56, 239/02, 261/06, 401/00, 403/02, 405/00, 413/00,
417/00

(21) International Application Number: PCT/US02/04608

(22) International Filing Date: 31 January 2002 (31.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/775,341 31 January 2001 (31.01.2001) US

(71) Applicant: **SYNAPTIC PHARMACEUTICAL CORPORATION** [US/US]; 215 College Road, Paramus, NJ 07652 (US).

(72) Inventors: **BLACKBURN, Thomas, P.**; 1 Fourteenth Street, Apt. 412, Hoboken, NJ 07030 (US). **KONKEL, Michael**; 69 MacArthur Avenue, Garfield, NJ 07026 (US). **BOTEJU, Lakmal, W.**; 39 Grissing Court, Cedar, NJ 07009 (US). **TALISMAN, Ian, Jamie**; 326 West 87th Street, Apt. 1F, New York, NY 10024 (US). **WETZEL, John, M.**; 23-17 Morlot Avenue, Fairlawn, NJ 07410 (US). **PACKIARAJAN, Mathivanan**; 275 Madison Avenue, Apt. #2, Saddle Brook, NJ 07663 (US). **CHEN, Heidi**; 376 Newtown Road, Wyckoff, NJ 07481 (US). **JIMENEZ, Hermo**; 80 Clarendon Pl., Apt. 10-A, Hackensack, NJ 07601 (US). **LAGU, Bharat**; 712 Primrose Court, Belle

Meade, NJ 08502 (US). **LIM, Kitae**; 24 King Street, Apt. #7, New York, NY 10014 (US). **NOBLE, Stewart**; 275 Oak Creek Drive, #407, Wheeling, IL 60090 (US).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
25 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



162162

WO 02/060392 A3

(54) Title: USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS

(57) Abstract: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.